Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zostavax Clinical Efficacy Trials For 50-59 Year-Olds Needed, Cmte. Says

Executive Summary

Merck should conduct full efficacy trials for its zoster vaccine Zostavax in adults aged 50-59, not just immunologic bridging studies, FDA's Vaccines & Related Biological Products Advisory Committee recommended at its Dec. 15 meeting

You may also be interested in...



Merck Zostavax Gets Mid-Range Price, Loses Younger Age Group

Merck's newly approved herpes zoster vaccine Zostavax is priced in the middle of the company's cost-effectiveness estimates

Merck Zostavax Gets Mid-Range Price, Loses Younger Age Group

Merck's newly approved herpes zoster vaccine Zostavax is priced in the middle of the company's cost-effectiveness estimates

Merck RotaTeq Observational Study For Intussusception Will Enroll 28,000

A post-marketing observational study for Merck's RotaTeq will enroll 28,000 patients to track reports of intussusception and other potential adverse events, the company told FDA's Vaccines & Related Biological Products Advisory Committee at its Dec. 14 meeting

Topics

UsernamePublicRestriction

Register

PS046694

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel